Renal function in abdominal neuroblastoma patients undergoing proton radiotherapy.
nephrotoxicity
neuroblastoma
proton therapy
radiation therapy
renal dysfunction
renal function
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
05
08
2022
received:
16
06
2022
accepted:
18
08
2022
pubmed:
22
9
2022
medline:
30
11
2022
entrez:
21
9
2022
Statut:
ppublish
Résumé
The purpose of this study is to analyze renal function outcomes in abdominal neuroblastoma patients undergoing proton therapy (PT). From 2011 to 2019, two single-institution Institutional Review Board-approved protocols prospectively enrolled neuroblastoma patients for data collection. To assess renal function, serum creatinine (Cr), blood urea nitrogen (BUN), and creatinine clearance (CrCl) before proton therapy (pre-PT) were compared with the values at last follow-up. A total of 30 children with abdominal neuroblastoma with median age 3.5 years (range, 0.9-9.1) at time of PT were included in this study. All patients underwent chemotherapy and resection of primary tumor prior to PT. Two patients required radical nephrectomy. Median follow-up after PT was 35 months. Mean dose to ipsilateral and contralateral kidney was 13.9 and 5.4 Gy, respectively. No patients developed hypertension or renal dysfunction during follow-up. There was no statistically significant change in serum BUN (p = .508), CrCl (p = .280), or eGFR (p = .246) between pre-PT and last follow-up. At a median follow-up of almost 3 years, renal toxicity was uncommon after PT. Longer follow-up and larger patient cohort data are needed to further assess impact of PT on renal function in this population.
Sections du résumé
BACKGROUND
The purpose of this study is to analyze renal function outcomes in abdominal neuroblastoma patients undergoing proton therapy (PT).
PROCEDURE
From 2011 to 2019, two single-institution Institutional Review Board-approved protocols prospectively enrolled neuroblastoma patients for data collection. To assess renal function, serum creatinine (Cr), blood urea nitrogen (BUN), and creatinine clearance (CrCl) before proton therapy (pre-PT) were compared with the values at last follow-up.
RESULTS
A total of 30 children with abdominal neuroblastoma with median age 3.5 years (range, 0.9-9.1) at time of PT were included in this study. All patients underwent chemotherapy and resection of primary tumor prior to PT. Two patients required radical nephrectomy. Median follow-up after PT was 35 months. Mean dose to ipsilateral and contralateral kidney was 13.9 and 5.4 Gy, respectively. No patients developed hypertension or renal dysfunction during follow-up. There was no statistically significant change in serum BUN (p = .508), CrCl (p = .280), or eGFR (p = .246) between pre-PT and last follow-up.
CONCLUSION
At a median follow-up of almost 3 years, renal toxicity was uncommon after PT. Longer follow-up and larger patient cohort data are needed to further assess impact of PT on renal function in this population.
Substances chimiques
Protons
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29981Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Brodeur GM, Hogarty MD, Mosse YP. In: Pizzo PA, Poplack DG, eds. Chapter 30: Neuroblastoma. Principles and practice of pediatric oncology. 6th ed. Wolters Kluwer/Lippincott Williams & Wilkins Health; 2011:886-923.
Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322(8):746-755.
Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-1334.
Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001;19(11):2821-2828.
Mazloom A, Louis CU, Nuchtern J, et al. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014;90(4):858-862.
Casey DL, Kushner BH, Cheung NK, et al. Local control with 21-Gy radiation therapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2016;96(2):393-400.
Bagley AF, Grosshans DR, Philip NV, et al. Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma. Pediatr Blood Cancer. 2019;66(8):e27786.
Dawson LA, Kavanagh BD, Paulino AC, et al. Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S108-S115.
Kunkler PB, Farr RF, Luxton RW. The limit of renal tolerance to x-rays; an investigation into renal damage occurring following the treatment of tumours of the testis by abdominal baths. Br J Radiol. 1952;25(292):192-201.
Mitus A, Tefft M, Fellers FX. Long-term follow-up of renal functions of 108 children who underwent nephrectomy for malignant disease. Pediatrics. 1969;44(6):912-921.
Peschel RE, Chen M, Seashore J. The treatment of massive hepatomegaly in stage IV-S neuroblastoma. Int J Radiat Oncol Biol Phys. 1981;7:549-553.
Esiashvili N, Chiang KY, Hasselle MD, et al. Renal toxicity in children undergoing total body irradiation for bone marrow transplant. Radiother Oncol. 2009;90:242-246.
Beckham TH, Casey DL, LaQuaglia MP, et al. Renal function outcomes of high-risk neuroblastoma patients undergoing radiation therapy. Int J Radiat Oncol Biol Phys. 2017;99:486-493.
Shull BC, Haughey D, Koup JR, et al. A useful method for predicting creatinine clearance in children. Clin Chem. 1978;24:1167-1169.
Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629-637.
Colantonio DA, Kyriakopoulou L, Chan MK, et al. Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem. 2012;58(5):854-868. 10.1373/clinchem.2011.177741
Dekkers IA, Blijdorp K, Cransberg K, et al. Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol. 2013;8:922-929.
Paulino AC, Wen BC, Brown CK, et al. Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys. 2000;46(5):1239-1246.
Irwin C, Fyles A, Wong CS, et al. Late renal function following whole abdominal irradiation. Radiother Oncol. 1996;38(3):257-261.
Kim TH, Somerville PJ, Freeman CR. Unilateral radiation nephropathy-the long-term significance. Int J Radiat Oncol Biol Phys. 1984;10:2053-2059.
Paganetti H, Blakely E, Carabe-Fernandez A, et al. Report of the AAPM TG-256 on the relative biological effectiveness of proton beams in radiation therapy. Med Phys. 2019;46:e53-e78.
Mohan R, Mahajan A, Minsky BD. New strategies in radiation therapy: exploiting the full potential of protons. Clin Cancer Res. 2013;19:6338-6343.
Sørensen BS, Bassler N, Nielsen S, et al. Relative biological effectiveness (RBE) and distal edge effects of proton radiation on early damage in vivo. Acta Oncol. 2017;56:1387-1391.
Upadhyay R, Liao K, Grosshans DR, et al. Quantifying the risk and Dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors. Neuro Oncol. 2022 Feb 14:noac44. 10.1093/neuonc/noac044